PT -期刊文章AU - p . j .西达盟- m . j .兄弟盟a Otte AU - t .葛瑞斯AU - r·钱伯斯AU - t·k·墨菲TI -普瑞巴林在中央神经性疼痛与脊髓损伤相关的援助——wnl.0000244422.45278 10.1212/01.。ff DP - 2006年11月28日TA -神经首页病学第六PG - 1792 - 1800 - 67 IP - 10 4099 - //www.ez-admanager.com/content/67/10/1792.short 4100 - //www.ez-admanager.com/content/67/10/1792.full所以Neurology2006 11月28日;中部67 AB -目的:评估与神经性疼痛与脊髓损伤有关。方法:12周,多中心研究的患者随机要么flexible-dose普瑞巴林150到600毫克/天(n = 70)或安慰剂(n = 67),进行报价。病人被允许保留在现有的稳定的疼痛治疗。主要疗效变量是端点代表痛苦得分,来自病人的最后7天每天疼痛日记。关键二次端点包括疼痛应答率,SF-MPQ,睡眠干扰,情绪,和病人全球的变化。结果:平均基线与组疼痛评分是6.54和6.73在安慰剂组。意味着端点与组的疼痛评分较低比安慰剂组(4.62)(6.27;p & lt;0.001),疗效观察早在第一周期间和维护。 The average pregabalin dose after the 3-week stabilization phase was 460 mg/day. Pregabalin was significantly superior to placebo in endpoint assessments on the SF-MPQ. The ≥30% and ≥50% pain responder rates were higher with pregabalin than placebo (p < 0.05). Pregabalin was associated with improvements in disturbed sleep (p < 0.001) and anxiety (p < 0.05), and more patients reported global improvement at endpoint in the pregabalin group (p < 0.001). Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events. Conclusions: Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury.